Legend Biotech to Participate in the Jefferies Global Healthcare Conference

Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN), a global leader in cell therapy, announced that CEO Ying Huang, Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference. This event will take place in New York, NY, on June 6, 2024, at 10:30 a.m. ET. Investors and other interested parties can view the live webcast through the Investor Relations section of Legend's website. A replay will be available approximately 48 hours after the event.

Positive

• Legend Biotech's participation in the Jefferies Global Healthcare Conference indicates strategic engagement with the investment community.
• Opportunity for the CEO to present current and future initiatives could attract new investors.
• Visibility at a high-profile event may enhance Legend Biotech's market presence and investor confidence.

Negative

• No significant business updates, financial data, or clinical trial results were provided in this announcement, which could be seen as a lack of substantial news.
• Investors looking for concrete data or outcomes may find this announcement lacking in actionable information.

SOMERSET, N.J.--(BUSINESS WIRE)-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.

The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend’s website. The webcast replay will be available approximately 48 hours after the webcast.

ABOUT LEGEND BIOTECH

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529662563/en/

INVESTOR CONTACT:

Jessie Yeung

Tel: (732) 956-8271

jessie.yeung@legendbiotech.com

PRESS CONTACT:

Mary Ann Ondish

Tel: (914) 552-4625

media@legendbiotech.com

Source: Legend Biotech Corporation

FAQ

What company will participate in the Jefferies Global Healthcare Conference?

Legend Biotech (NASDAQ: LEGN) will participate.

When will Legend Biotech's CEO participate in the Jefferies Global Healthcare Conference?

On June 6, 2024, at 10:30 a.m. ET.

Who is representing Legend Biotech at the Jefferies Global Healthcare Conference?

CEO Ying Huang, Ph.D., will represent the company.

How can investors watch Legend Biotech's fireside chat at the Jefferies Global Healthcare Conference?

Investors can watch via live webcast on the Investor Relations section of Legend Biotech's website.

Will a replay be available for Legend Biotech's presentation at the Jefferies Global Healthcare Conference?

Yes, a replay will be available approximately 48 hours after the webcast.